{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:14:08Z","timestamp":1770822848835,"version":"3.50.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bulcan.2025.10.004","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:33:43Z","timestamp":1765802023000},"page":"135-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acalabrutinib en association \u00e0 la bendamustine et au rituximab en traitement de premi\u00e8re ligne du lymphome \u00e0 cellules du manteau chez les patients \u00e2g\u00e9s"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7960-7330","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"Piron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl_4","key":"10.1016\/j.bulcan.2025.10.004_bib0035","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.10.004_bib0040","series-title":"Poster pr\u00e9sent\u00e9 au 45e Congr\u00e8s Annuel de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019h\u00e9matologie (SFH)\u00a0; 2025\u00a0avril 2\u20134\u00a0; Paris, France","article-title":"Prise en charge des lymphomes \u00e0 cellules du manteau en vie r\u00e9elle dans la cohorte fran\u00e7aise REAYSA\u00a0: \u00e9tude MCL_TOUR","author":"Tessoulin","year":"2025"},{"issue":"26","key":"10.1016\/j.bulcan.2025.10.004_bib0045","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bulcan.2025.10.004_bib0050","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.bulcan.2023.07.002","article-title":"Pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed\/refractory (R\/R) mantle cell lymphoma","volume":"110","author":"Fileni","year":"2023","journal-title":"Bull Cancer (Paris)"},{"issue":"10121","key":"10.1016\/j.bulcan.2025.10.004_bib0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.bulcan.2025.10.004_bib0030","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","author":"Wang","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512500520X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512500520X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:30:11Z","timestamp":1770820211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512500520X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S000745512500520X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.10.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acalabrutinib en association \u00e0 la bendamustine et au rituximab en traitement de premi\u00e8re ligne du lymphome \u00e0 cellules du manteau chez les patients \u00e2g\u00e9s","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}